Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a High Proportion of Patients with Locally Advanced dMMR Colon Cancer
Findings from the NICHE-2 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1585 results
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
Evidence for efficacy is based on the results from the TRANSCEND-MCL study
Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab in Resectable, Macroscopic Stage III Melanoma
Findings from NADINA study
EMA Recommends Extension of Therapeutic Indications for Tislelizumab
New indications concern the treatment of patients with locally advanced or metastatic NSCLC
Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage III EGFR-mutated NSCLC
Findings from the LAURA study
Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation
Findings from a pre-specified translational analysis of the MITO END-3 study
Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who Relapse Within 12 Months of Standard-of-Care Chemotherapy or Surgery for Early TNBC
Overall survival results from the IMpassion132 study
FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma
Evidence for efficacy is based on the results from the TRANSCEND-FL study
Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient mCRC Treated with ICIs Surpass the Benefit Observed in dMMR/MSI-H mCRC
Findings from a global study in patients with mCRC harbouring POLE/D1 mutations
EMA Recommends Granting a Marketing Authorisation for Generic Eribulin
Eribulin Baxter is a generic of Halaven, which has been authorised in the EU since 2011
Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced HCC Who Were Sorafenib Intolerant or Refractory
5-year results from the CheckMate 040 study
Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with Prostate Cancer Treated with Postoperative Radiotherapy
Findings from the RADICALS-HD study